Antiretroviral Combinations
Phase 2Small molecule
GileadAntiretroviral Combinations is one of 41 small molecule programs targeting Mortality. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
108 competitors in Mortality
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaPhase 3
Mounjaro
Eli LillyPhase 3
Winrevair
Merck & Co.Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Prometrium
FerringPhase 3
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Peridex
MMedline Industries
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mortality1 trial
Outcome1 trial
Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
Recruiting·—·Phase 3·NCT06507059·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antiretroviral Combinations. EMBL-EBI & Wellcome Sanger Institute.
- [4]